Recent Press Releases

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License...

Nation's largest distributor of influenza vaccines prepared to respond to vaccine delays

Despite multiple manufacturers experiencing delays, FFF has large quantities immediately available TEMECULA, Calif., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Unexpected delays from multiple manufacturers...

Vaxart's Tablet Vaccine for H1N1 Influenza Generates Protective Immunity Equivalent to Injectable in Phase I Clinical Study

Data Presented at World Vaccine Congress 2014 in Brussels SOUTH SAN FRANCISCO, CA, USA I October 14, 2014 I Vaxart, Inc., a privately held, clinical-stage company developing recombinant vaccines...

Baxter's Third Quarter Financial Results Exceed Guidance

Company Bolsters Portfolio, Achieves Significant Pipeline Milestones and Progresses Toward Separation DEERFIELD, Ill., October 16, 2014 - Baxter International Inc. (NYSE:BAX) today posted strong...

Ebola vaccine trials beginning in Mali

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced...

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Joint Support by Sanofi and JDRF Funds Ongoing Program for First-In-Class, Antigen-Specific Product to Target Autoimmunity Underlying Type 1 Diabetes WATERTOWN, Mass. – October 15, 2014...

Shantha's Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India

- The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea - Lyon, France - October 14, 2014 - Sanofi Pasteur, the vaccines...

Candidate H7N9 Avian Flu Vaccine Works Better with Adjuvant

Results of Large NIH-Sponsored Trial Published An experimental vaccine to protect people against H7N9 avian influenza prompted immune responses in 59 percent of volunteers who received two...

Takeda invests in Vaccine Safe Co., a subsidiary wholly-owned by Alfresa Corporation

Osaka, Japan, October 2, 2014 – Takeda Pharmaceutical Company Limited ("Takeda") announces today that it has decided to invest in Vaccine Safe Co. (Head Office: Chiyoda, Tokyo) which...

Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company's investigational...

PNAS Modeling Study Finds TB Vaccines for Adolescents/Adults Cost-Effective Even With Low Efficacy

ROCKVILLE, MD, USA, OCTOBER 8, 2014 — A new study published in the Proceedings of the National Academy of Sciences released this week finds that a tuberculosis (TB) vaccine could have an...

Changes to the Novartis Executive Committee after expected completion of portfolio transactions

(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Changes to the Novartis Executive Committee after expected completion of portfolio transactions . Processed and transmitted by NASDAQ...

Takeda Appoints New Head of Vaccine Development

DEERFIELD, Ill., Oct 07, 2014 (BUSINESS WIRE) -- Takeda Pharmaceuticals International, Inc. ("Takeda") announced today that John Boslego, MD, has been named Senior Vice President and Head...

Statement regarding interim findings of WHO assessment of deaths of children in Idleb Governorate, Syria

Statement 27 September 2014 A WHO assessment of the cause of the death of 15 children in rural Idleb, northern Syria has concluded that the most likely cause of the event was the incorrect use...

Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute

EPALINGES, SWITZERLAND, Sep 29, 2014 (Marketwired via COMTEX) -- Mymetics Corporation (otcqb:MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of...

MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma

SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug...

Dr. Jon Andrus Named Executive Vice President of the Sabin Vaccine Institute

WASHINGTON, D.C. — September 25, 2014 — The Sabin Vaccine Institute (Sabin) today announced that effective October 17, 2014, Dr. Jon Andrus will join Sabin as Executive Vice President...

Sanofi Pasteur Introduces 4-Strain Influenza Vaccine in Canada

Sanofi Pasteur, the vaccines division of Sanofi, is pleased to announce the launch of its 4-strain influenza vaccine (Fluzone(®) Quadrivalent) in Canada. This new vaccine was introduced in the...

Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

PHILADELPHIA — Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to...

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

Princeton, NJ – September 19, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs...